SunGen Pharma aims to create a healthier future for patients while increasing shareholder value through the development and introduction of quality, affordable generic products by experienced, passionate and talented pharmaceutical professionals.
SunGen Pharma is a specialty pharmaceutical company focused on development, manufacturing and marketing of high quality generic prescription pharmaceuticals that improve patient's health while creating stakeholder value. We specialize in difficult-to-manufacture and high barrier to entry complex dosage forms, including ophthalmics, injectables, topicals and oral solids. SunGen has Research and Development facilities in Monmouth Junction and Princeton, NJ, and several manufacturing facilities across North America and Asia through partnership and contract manufacturing.
SunGen has over 40 products under development at various stages that have have been and will be filed with the FDA and Chinese FDA through different partnerships. These products cover multiple dosage forms including oral solids, topicals, and injectables.
SunGen Pharma is seeking pharmaceutical licensing, acquisition, and partnership opportunities for ANDA products that are already marketed or currently approved. We also are seeking for joint product development (ANDA, NDA, 505(b)(2)) for US and international markets.
Working Together for a Healthier Future
- Licensing (ANDA, NDA) and asset purchases
- Joint product development (ANDA, 505(b)(2))
- International product registrations
- Sales, marketing, and distribution of approved products in the United States
SunGen has an extensive partnership network in Asia, the United States and Europe. Our partners look to us for collaborative development and marketing of various products in the United States. SunGen has manufacturing, marketing, and development partners throughout North America and Asia.
SunGen Pharma announces affiliation with Geneyork Pharmaceuticals, a joint venture with Tianjin Kingyork Group Co., Ltd. Geneyork, formed in 2017, specializes in drug research and development fo...Read More
SunGen Pharma Receives Seventh ANDA Approval from US FDA
SunGen's seventh approved ANDA is for Fosaprepitant for Injection 150mg/vial. This drug product is used for treatment of cyclic vomiting syndrome and late-stage chemotherapy induced vomiting. This ...Read More
Elite Pharmaceuticals and SunGen Pharma File ANDA for Extended-Release CNS Stimulant
Elite Pharmaceuticals, Inc. a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it has filed an Abbreviated New Drug Application (...Read More
Get In Touch
SUNGEN PHARMA LLC
303C College Rd East
Princeton, NJ 08540
SUNGEN PHARMA LLC
9 Deerpark Dr, Suite J-10
Monmouth Junction, NJ 08852
Email : firstname.lastname@example.org
Phone :(609) 606-1060